{"entity": "publication", "iuid": "9fed098cab224c91b4f08be19cef2b9e", "timestamp": "2026-08-20T20:36:18.027Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/9fed098cab224c91b4f08be19cef2b9e.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/9fed098cab224c91b4f08be19cef2b9e"}}, "title": "Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas.", "authors": [{"family": "Ma", "given": "Jing", "initials": "J"}, {"family": "Sar\u00e9n", "given": "Tina", "initials": "T"}, {"family": "Jin", "given": "Chuan", "initials": "C"}, {"family": "Kim", "given": "Hyeong Su", "initials": "HS"}, {"family": "Contreras Pineda", "given": "Paola Donaji", "initials": "PD"}, {"family": "de Bernard", "given": "Marina", "initials": "M"}, {"family": "Amini", "given": "Rose-Marie", "initials": "RM"}, {"family": "Rondahl", "given": "Veronica", "initials": "V"}, {"family": "Enblad", "given": "Gunilla", "initials": "G"}, {"family": "Yu", "given": "Di", "initials": "D"}, {"family": "Essand", "given": "Magnus", "initials": "M"}], "type": "journal article", "published": "2025-07-12", "journal": {"title": "Cancer Immunol. Immunother.", "issn": "1432-0851", "volume": "74", "issue": "8", "pages": "262", "issn-l": "0340-7004"}, "abstract": "CD19 CAR-T cell therapy shows striking results in treating B cell malignancies. However, approximately two-thirds of the lymphoma patients eventually relapse, with about one-third displaying CD19-negative tumors at relapse. Our previous study showed that CAR-T cells armed with the Helicobacter pylori neutrophil-activating protein (NAP), CAR(NAP)-T cells, can trigger a bystander immune response and eliminate CAR-target-antigen-negative tumor cells. Here, we report the development of CD20-targeted CAR-T cells (CAR20-T cells), with the targeting moiety from rituximab, and the safety and efficacy of NAP-armed CAR-T cells. CAR20-T cells displayed efficient and specific cytotoxic potential against multiple human B cell lymphoma cell lines in vitro. In addition, primary mantle cell lymphoma cells, isolated from a patient who relapsed after rituximab treatment, can also be eliminated by CAR20-T cells. CAR20(NAP)-T cells delayed tumor growth and prolonged survival of mice with lymphoma. No obvious histopathological alteration in major organs were observed in mice treated with CAR(NAP)-T cells. Further, no excessive cytokine release or immune cell activation was observed when human blood from healthy volunteers was exposed to recombinant NAP protein in an ex vivo blood loop assay, suggesting a safe therapeutic profile for NAP. Taken together, these results warrant the clinical investigation of CAR20(NAP)-T cells.", "doi": "10.1007/s00262-025-04112-1", "pmid": "40650770", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12255594"}, {"db": "pii", "key": "10.1007/s00262-025-04112-1"}], "notes": [], "created": "2026-08-20T06:39:36.089Z", "modified": "2026-08-20T06:39:36.145Z"}